+ Watch ONXX
on My Watchlist
A biopharmaceutical company building an oncology business by developing and commercializing innovative therapies that target the molecular mechanisms implicated in cancer.
ONXX reports strong revenue growth on Nexavar sales. 2008 Nexava Net sales of $678M, 82% annual growth, makes 2008 the first full year profitable although more R&D cost. New indications are progressing well. A long position for a long time.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions